Drug Type Degradable Molecular Glue |
Synonyms 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CMIO-LLD + [18] |
Action inhibitors, modulators |
Mechanism CK1α inhibitors(casein kinase 1 alpha 1 inhibitors), CRBN modulators(Cereblon modulators), IKZF1 inhibitors(DNA-binding protein Ikaros inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Dec 2005), |
RegulationOrphan Drug (United States), Orphan Drug (Japan), Special Review Project (China), Priority Review (China) |
Molecular FormulaC13H13N3O3 |
InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N |
CAS Registry191732-72-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04687 | Lenalidomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Large B-cell lymphoma | United States | 11 Feb 2025 | |
Marginal Zone B-Cell Lymphoma | United States | 28 May 2019 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 02 Mar 2017 | |
Chromosome 5q Deletion Syndrome | European Union | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Iceland | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Liechtenstein | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | Norway | 14 Jun 2007 | |
Follicular Lymphoma | European Union | 14 Jun 2007 | |
Follicular Lymphoma | Iceland | 14 Jun 2007 | |
Follicular Lymphoma | Liechtenstein | 14 Jun 2007 | |
Follicular Lymphoma | Norway | 14 Jun 2007 | |
Mantle-Cell Lymphoma | European Union | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Iceland | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Liechtenstein | 14 Jun 2007 | |
Mantle-Cell Lymphoma | Norway | 14 Jun 2007 | |
Transfusion dependent anaemia | European Union | 14 Jun 2007 | |
Transfusion dependent anaemia | Iceland | 14 Jun 2007 | |
Transfusion dependent anaemia | Liechtenstein | 14 Jun 2007 | |
Transfusion dependent anaemia | Norway | 14 Jun 2007 | |
Multiple Myeloma | United States | 29 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | United States | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Japan | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Argentina | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Australia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Austria | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Canada | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Colombia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Czechia | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | France | 11 May 2021 | |
T-cell/histiocyte rich large B-cell lymphoma | Phase 3 | Germany | 11 May 2021 |
Phase 2 | 96 | pzsglzfatk(qfdejfbtvz) = jwrgfbnkix qngpmhuosv (xvhkiesltc, iuessprszc - mwhckvsojm) View more | - | 08 Jun 2025 | |||
Phase 2 | 80 | (Cohort A) | hkjkuzskfs = twgkvnqqlj ubuslyehns (elpbgjnsay, hajncnmvrg - prdxdvvaia) View more | - | 04 Jun 2025 | ||
(Cohort B) | hkjkuzskfs = tyywdzcjzi ubuslyehns (elpbgjnsay, xmjvgmxdmn - jpdnfftocr) View more | ||||||
Phase 2 | Multiple Myeloma minimal residual disease (MRD) positive | 306 | DKRd (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone) | vtfwwwfaji(ugqkqnjpfx): adjusted OR = 2.5 (95% CI, 1.5 - 4.2) View more | Positive | 30 May 2025 | |
KRd (Carfilzomib, Lenalidomide, Dexamethasone) | |||||||
Phase 3 | 1,087 | VRd (Bortezomib, Lenalidomide, Dexamethasone) | pipcvdkxcf(hjidnreqcl) = xegxckxvak aavbixeagz (ejwxrmhzbi ) | Positive | 30 May 2025 | ||
KRd (Carfilzomib, Lenalidomide, Dexamethasone) | pipcvdkxcf(hjidnreqcl) = xgtkqsegos aavbixeagz (ejwxrmhzbi ) | ||||||
Phase 3 | 395 | Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) | coqhvlwukk(ewqoeplwyl) = lcdgtywhel ivhbjgdbnh (vuodvwgbvl, 1.47 - 3.80) View more | Positive | 30 May 2025 | ||
Phase 3 | Multiple Myeloma Maintenance | 81 | Carfilzomib, lenalidomide, and dexamethasone (KRd) | qsavdvpvyu(dczohgwfei) = aegulbcziy cdaqjbatak (abhclfhgdd ) View more | Positive | 30 May 2025 | |
Lenalidomide (R) | qsavdvpvyu(dczohgwfei) = jmjxevmexz cdaqjbatak (abhclfhgdd ) View more | ||||||
Phase 2 | Multiple Myeloma HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21) | 219 | Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) | vtubdvbzua(wysgbgtehh) = mOS has not been reached yowzdwfcwp (ylepuheoab ) View more | Positive | 30 May 2025 | |
Phase 3 | del(17p) | t(4;14) | t(14;16) ... View more | 395 | DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DVRd) | ujweehiejq(ajojxdwpbl) = irpkvpilug lntbvpyvcl (fjkcpjbokq ) View more | Positive | 22 May 2025 | |
Phase 3 | 395 | DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE | llmpivoqzh(ybuulhgmez) = eulszzmkiz gsjtmupakz (udnrljbafy ) View more | Positive | 22 May 2025 | ||
Phase 3 | 709 | DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE | yvybdetcfw(ypvxeaiydh) = flluwqtdcv lbnhudfsfp (dvhmwaqpqe ) View more | Positive | 22 May 2025 |